Pfizer Inc

• Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial - The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.
• Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook - The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.
• What obesity drugmakers see next in the market: More pills, easier access and drug combinations - CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in San Francisco.
• 2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market - Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year.
• Nine of the largest pharma companies ink deals with Trump to lower drug prices - President Donald Trump has pushed to lower drug prices for Americans, which are on average nearly three times higher than overseas.
• Wall Street banked on a flurry of deals under Trump in 2025. It wasn't that simple - Dealmakers expected a flood of M&A to take place in 2025 following the election of President Trump. The number of transactions didn't live up to the hype.